Piotroski F-score
Failed
1 check could not be answered: a figure either filed year needs is missing, not evidence either way.
CGEN reported revenue of $72.76M and net income of $35.34M in FY2025.
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $72.76M | $35.34M |
| 2024 | $27.86M | −$14.23M |
| 2023 | $33.46M | −$18.75M |
14 more years are on Measure
Free, no card, and it does not expire. See what the paid plans add
Also filed under Biotechnology, ranked by how closely they sit beside CGEN.
CGEN is among the largest companies matching:
The assistant answers from what CGEN has actually filed: 17 annual reports filed with the SEC, 34 Form 4 filings from the last year and 1 fund that holds it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.
Press one and the answer appears right here on the page, from CGEN's filings and figures. One a day without an account; a free account has its own, and no card.
Cash flow breakdown
What the business generated, and where it went
Operating cash flow
$31.63M 2025
Cash generated by the business itself
Free cash flow
$31.33M 2025
Operating cash flow minus capital expenditure
Capital expenditure
$306K 2025
Spending on property, plant and equipment
CGEN generated $31.63M of operating cash flow. Each figure below is what it did with that, as reported on the same statement.
Reinvested in the business
A non-cash cost, added back above
As reported in the company's own annual filings.
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $31.63M | $49.6M | −$35.89M | −$34.11M | −$22.69M | −$28.32M | −$27.89M | −$13.29M | −$30.66M | −$19.82M | −$25.61M | −$11.15M | −$6.44M | −$10.85M | −$9.25M | −$4.28M | −$7.45M |
Financial statements
Every figure below is this company’s, as filed. Measure draws them: 17 years and 0 quarters plotted to scale, on the income statement, balance sheet and cash flow, plus the ratio and estimate sections this page does not carry.
Free, no card, and it does not expire. See what the paid plans add
As reported in the company's own annual filings.
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72.76M | $27.86M | $33.46M | $7.5M | $6M | $2M | - | $17.8M | - | $712K | $9.28M | $12.37M | $3.55M | $242K | - | $1.12M | $250K |
| Cost of revenue | $9.25M | $7.93M | $2M | $975K | $680K | $60K | - | $1.03M | - | $223K | $1.63M | $3.34M | $2.51M | $201K | - | $224K | - |
| Gross profit | $63.51M | $19.93M | $31.46M | $6.53M | $5.32M | $1.94M | - | $16.77M | - | $489K | $7.64M | $9.02M | $1.04M | $41K | - | $891K | $250K |
| Research and development | $22.76M | $24.81M | $34.47M | $30.65M | $28.69M | $22.76M | $19.82M | $30.32M | $28.58M | $24.55M | $21.25M | $15.07M | $12.28M | $9.44M | $6.78M | $5.23M | $5.05M |
| Selling, general and administrative | $8.89M | $9.44M | $9.73M | $10.32M | $10.86M | $9.81M | $8.41M | $8.04M | $7.63M | $7.35M | $6.01M | $5.45M | $4.85M | $3.46M | $4.59M | $2.91M | $2.15M |
| Operating income | $31.33M | −$14.89M | −$12.99M | −$35.37M | −$35.07M | −$31.5M | −$28.88M | −$23.23M | −$37.41M | −$32.58M | −$20.92M | −$12.34M | −$17.04M | −$13.54M | −$11.98M | −$7.88M | −$7.63M |
| Net income | $35.34M | −$14.23M | −$18.75M | −$33.69M | −$34.2M | −$29.7M | −$27.34M | −$22.6M | −$37.07M | −$31.51M | −$20.16M | −$11.09M | −$14.08M | −$13.63M | −$12M | −$7.2M | −$3.83M |
| Diluted EPS | $0.38 | -$0.16 | -$0.21 | -$0.39 | -$0.41 | -$0.37 | -$0.43 | -$0.41 | -$0.72 | -$0.62 | -$0.40 | -$0.26 | -$0.36 | -$0.38 | -$0.35 | - | - |
| Diluted shares | 93.82M | 89.53M | 87.63M | 86.56M | 84.2M | 79.59M | 63.64M | 55.28M | 51.18M | 50.86M | 50.44M | 48.39M | 38.87M | 36.25M | 34.28M | 33.28M | - |
| Gross margin | 87.29% | 71.54% | 94.01% | 87.00% | 88.67% | 97.00% | - | 94.19% | - | 68.68% | 82.40% | 72.96% | 29.30% | 16.94% | - | 79.91% | 100.00% |
| Operating margin | 43.05% | −53.44% | −38.83% | −471.65% | −584.57% | −1574.80% | - | −130.49% | - | −4576.26% | −225.48% | −99.76% | −480.22% | −5595.87% | - | −706.55% | −3051.60% |
| Net margin | 48.57% | −51.07% | −56.05% | −449.25% | −570.05% | −1484.90% | - | −126.96% | - | −4425.00% | −217.34% | −89.71% | −396.82% | −5631.40% | - | −646.01% | −1532.40% |
Total assets
Plotted to scale onMeasure
Total liabilities
Plotted to scale onMeasure
Shareholder equity
Plotted to scale onMeasure
Cash
Plotted to scale onMeasure
Current assets
Plotted to scale onMeasure
Current liabilities
Plotted to scale onMeasure
Short-term investments
Plotted to scale onMeasure
As reported in the company's own annual filings.
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $156.57M | $115M | $121.33M | $94.18M | $132.16M | $138.32M | $53.76M | $53.18M | $38.75M | $71.14M | $99.31M | $114.99M | $56.71M | $28.91M | $29.08M | $36.46M | - |
Market cap
Plotted to scale onMeasure
Enterprise value
Plotted to scale onMeasure
Computed against the closing price on each fiscal year end, not reported by the company.
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Market cap | $142.94M | $136.98M | $173.51M | $61.95M | $362.08M | $963.85M | $379.27M | $119.95M | $127.95M | $259.37M | $322.29M | $398.25M | $347.88M | $176.35M | $169.67M | $163.76M | - |
Derived from SEC XBRL filings. Not investment advice.
See every filed year for CGEN, quarter by quarter.
Ten seconds. No card. Nothing to cancel.
Be told the next time CGEN files
Watch CGEN and every quarterly and annual report, material 8-K, open-market Form 4 worth a row and tracked manager's change lands in the bell and a daily email. Free.
See all 17 filed years plotted, not just read
Every annual statement CGEN has filed is on this page as figures. Drawn to scale, a trend over the whole record is something you can see rather than something you have to add up.
The charts, to scaleMeasure
Catch a turn before the year confirms it
Revenue, margins and cash flow quarter by quarter, where a change in direction shows up first.
Quarterly statementsMeasure
Ask why a number moved, get the filing back
Why a margin moved, where the cash went: answered from CGEN's own statements, not a guess.
Free, no card, and it does not expire.
| Capital expenditure | $306K | $118K | $172K | $477K | $292K | $166K | $155K | $158K | $385K | $2.6M | $3.12M | $1.9M | $328K | $1.01M | $96K | $46K | $48K |
|---|
| Free cash flow | $31.33M | $49.49M | −$36.06M | −$34.59M | −$22.98M | −$28.49M | −$28.04M | −$13.45M | −$31.04M | −$22.42M | −$28.73M | −$13.04M | −$6.77M | −$11.85M | −$9.35M | −$4.33M | −$7.5M |
|---|
| Stock-based compensation | $1.88M | $3.02M | $3.55M | $4.33M | $4.28M | $2.77M | $2.41M | $2.17M | $2.63M | $3.08M | $3.77M | $3.63M | $3.54M | $2.47M | $3.4M | $2.34M | $1.53M |
|---|
| Current assets | $148.02M | $106M | $114.58M | $86.13M | $123.22M | $129.09M | $45M | $46.58M | $31.18M | $62.68M | $91M | $75.1M | $53.22M | $25.57M | $23.01M | $28.08M | - |
|---|
| Cash | $90.6M | $18.23M | $13.89M | $11.06M | $7.8M | $7.14M | $9.19M | $5.86M | $25.47M | $9.71M | $10.78M | $25.64M | $28.75M | $16.37M | $5.85M | $7.3M | $15.14M |
|---|
| Short-term investments | $45.76M | $61.4M | $25.05M | $72.29M | $109.25M | $116.62M | $34.04M | $39.21M | $3.92M | $50.83M | $69.57M | $47.14M | $18.02M | $3.22M | $16.53M | $14.52M | - |
|---|
| Total liabilities | $53.84M | $60.08M | $55.78M | $16.5M | $25.47M | $18.53M | $15.44M | $15.94M | $9.45M | $7.62M | $9.41M | $8.87M | $24.82M | $11.24M | $9.5M | $8.17M | - |
|---|
| Current liabilities | $22.57M | $20.16M | $26.27M | $11.92M | $17.1M | $10.52M | $6.82M | $9.99M | $6.19M | $4.74M | $6.85M | $6.59M | $7.74M | $1.38M | $1.42M | $2.44M | - |
|---|
| Shareholder equity | $102.73M | $54.91M | $65.56M | $77.68M | $106.69M | $119.78M | $38.32M | $37.24M | $29.3M | $63.52M | $89.9M | $106.12M | $31.89M | $17.67M | $19.58M | $28.29M | $27.4M |
|---|
| Enterprise value | $52.34M | $118.75M | $159.62M | $50.89M | $354.28M | $956.71M | $370.09M | $114.09M | $102.48M | $249.66M | $311.52M | $372.6M | $319.13M | $159.98M | $163.82M | $156.46M | - |
|---|
| Price at year end | $1.53 | $1.53 | $1.98 | $0.72 | $4.30 | $12.11 | $5.96 | $2.17 | $2.50 | $5.10 | $6.39 | $8.33 | $8.95 | $4.92 | $4.95 | $4.92 | $4.85 |
|---|
| P/E ratio | 4.03 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|---|
| Price to free cash flow | 4.56 | 2.77 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|---|